Date:- 29 March, 2018
- COLOSSUS aim is to better stratify metastatic colorectal patients for improving treatments
- The project gathers a large European consortium of leading cancer centers and private companies
- HalioDx is exploring immuno-oncology mechanisms to contribute to the identification of new treatment strategies in this difficult-to-treat patient population
HalioDx SAS, an immuno-oncology diagnostic company, announced its participation in the COLOSSUS project, led by the RCSI (Royal College of Surgeons in Ireland), conducted in close collaboration with prestigious clinical research centers in Europe and supported by the European Commission’s Horizon 2020 program. The project will run for 5 years and formally started in January 2018.
COLOSSUS is funded by an EU-Horizon 2020 grant, named “New concepts in patient stratification” and was ranked #1 out of 206 applications submitted to H2020 Personalized Medicine Call from across Europe in 2017.
The COLOSSUS project (€ 6 millions) aim is to provide new and more effective stratification tools and therapeutic interventions, specifically tailored to a genetically defined form of metastatic (m) colorectal cancer (CRC) called microsatellite stable (MSS) RAS mutant (mt) disease which is incurable once patients develop resistance to existing therapies. The project gathers a large European consortium of leading cancer centers from Ireland, Spain, UK, Belgium, Germany, and Italy. The project is led by Professor Annette Byrne, Associate Professor, RCSI Dept of Physiology and Medical Physics and RCSI Centre for Systems Medicine and the scientific Programme is jointly directed by Dr Rodrigo Dienstmann (VHIO, Barcelona, Spain) and Prof Jochen Prehn (RCSI, Dublin, Ireland).
The project will focus on the critical requirement for in-depth biological interrogation and refinement of CRC subtypes, in particular to deliver new models for MSS RAS mt patient stratification and treatment that take into consideration not only genomics and transcriptomics but also epigenomics, proteomics, metabolic and immunological features.
Immunoscore® Colon and newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial, a multicentre clinical study for advanced MSS RAS mt mCRC patients which will be conducted across Spain, Germany and Ireland.
Vincent FERT, CEO of HalioDx comments:
“HalioDx is very excited to be part of the COLOSSUS consortium to drive medical innovation for patient’s care. This project is uniquely positioned to perform novel and integrated pathway analyses and to deliver and robustly test novel MSS RAS mt classifiers and new combinatorial therapeutic strategies. Working with the project leading experts in colorectal cancer, we are committed to demonstrate that our biomarker technology is broadly applicable in Immuno-oncology diagnostics. ”